Evaxion Biotech A/S Overview
Valuation check: EVAX's P/E ratio is -2.16, below the Healthcare sector average of 26.85.
Get informed when a big investor buys or sells
+ Follow-2.16
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for EVAX is -2.16. That is below the Healthcare sector average of 26.85. Investors often review this figure alongside Evaxion Biotech A/S's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, EVAX currently prints -2.16 for P/E ratio, while the sector average sits near 26.85. That is roughly 108.0% below the sector mean. Large gaps often invite a closer look at Evaxion Biotech A/S's growth, margins, and balance sheet.
A P/E ratio of -2.16 for Evaxion Biotech A/S is not 'good' or 'bad' on its own. Compare it with the peer average (26.85) and with EVAX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting EVAX's P/E ratio (-2.16), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Evaxion Biotech A/S's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
